Home | NexPlasmaGen
15847
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-15847,bridge-core-2.6.4,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-24.9,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,qode-wpml-enabled,wpb-js-composer js-comp-ver-7.7,vc_responsive

FACTS

Breast Conserving Therapy (BCT)

 

Worldwide over 1 million women diagnosed with breast cancer undergo BCT (surgery with follow-up radiotherapy) annually as an alternative to mastectomy, whereby both procedures result in comparable survival rate for early breast cancer.

BCT Recurrence

 

The current standard of care recommending BCT suffers up to 15% recurrence rate within 10 years due to positive margin (residual cancer cells in the tumor bed after solid tumor removed).

Breast Cancer Survival

 

5-years residual risks of recurrence for patients with stage I, II, III and IV cancers are about 7%, 11%, 13% and >20% respectively,  relating to 5-years survival rate of 100%, 93%, 72% and 22% respectively.

10

Number of peer-reviewed scientific papers

9

Number of projects completed

2

Number of patents and patent pending

27

Number of conferences

TEAM

Valérie Léveillé, Eng., M. Eng., PhD
CEO / Founder

Valérie has 16-yr experience in technology R&D, design and commercialization. She is co-inventor of NexPlasmaGenTMs technology.

Audrey Glory, PhD
Preclinical trials leader

Audrey has 5-yr experience in conducting preclinical trials for breast and other cancers. She works at NexPlasmaGen and at the CR-CHUM.

Philip Wong, MDCM, MSc, FRCPC
Medical Advisor

Philip is an Assistant Professor at the Department of Radiation Oncology, University of Toronto. He is a clinician-investigator at the CR-CHUM. He leads NexPlasmaGen’s clinical program and is co-inventor of NexPlasmaGen’s technology.

Julie Lafontaine, PhD
Laboratory supervisor, CR-CHUM

Julie has 7-yr experience supervising Dr. Wong’s laboratory and plays a crucial role in NexPlasmaGen preclinical trials. She works at the CR-CHUM.

BOARD DIRECTORS

Valérie Léveillé, Eng., M. Eng., PhD
Board member and CEO

David Uffer, M.A., MBA

Managing Director MedTech, Trinity Life Sciences

30 years commercializing medical devices

Past: VP Medtech General Inception, BD Director, Covidien (now Medtronic) Hologic, Boston Scientific, VP at Bovie Medical

SCIENTIFIC ADVISORY COMMITTEE

Philip Wong

MDCM, MSc, FRCPC

Associate Professor, Department of Radiation Oncology, University of Toronto

Clinician-investigator-Princess Margaret Cancer Centre

Louis Gaboury

M.D., Ph.D., FRCP(C)

IRIC Histology Platform Professor, Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal Anatomic-Pathologist, CHUM

Erica Patocskai

MD, FRCSC

Chief, Surgical Oncology Service, CHUM

Associate clinical professor, Department of Surgery, Faculty of Medicine, University of Montreal

Jean-François Lapointe

Ph.D.

Consultant, Regulatory and Clinical Affairs
Lok North-America

BUSINESS ADVISORY COMMITTEE

David Uffer

MBA, B.A.

Managing Director MedTech, Trinity Life Sciences

30 years commercializing medical devices

Past: VP Medtech General Inception, BD Director, Covidien (now Medtronic) Hologic, Boston Scientific, VP at Bovie Medical

Sohaib Siddiqui

B.ScH, MD, FRCSI  

EIR @ TIAP & Faculty of Medicine

Innovation Fellow at Women’s College

Managing Partner, Kettlebeck Ventures

Edward J. Dougherty

B.A., M.S., Th.M.

Principal at dougherty.consulting, llc,

30 years in regulatory and reimbursement for medical devices

Samuel Ohayon

B.S., M.S.

Entrepreneur in Residence at CTS

Venture Partner for Health Tech funds

Health Tech Executive

Biotech Entrepreneur

Trained as a Molecular Pathologists

See our partners who support the company and our technology development

Supported in part by advisory services and research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP)
CLIEO

You met the team, now meet our technology!